Categories
Change Password!
Reset Password!
Elagolix effectively mitigates pain in premenopausal women with endometriosis in the short to mid-term. However, vigilant monitoring for adverse effects is crucial during treatment.
Endometriosis is a painful condition affecting many women, and Elagolix (a non-peptide gonadotropin-releasing hormone [GnRH] antagonist) has emerged as a potential treatment. This systematic review and meta-analysis published in the “Journal of Gynecology Obstetrics and Human Reproduction” analyzed five randomized controlled trials (RCTs) with 2,056 participants, revealing that the Elagolix dramatically alleviates endometriosis pain, including non-menstrual pelvic pain, dysmenorrhea, and dyspareunia.
Comprehensive searches were conducted across databases like PubMed, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Library, focusing on RCTs that compared Elagolix with placebo for tackling endometriosis discomfort. The studies were evaluated for quality using a bias risk assessment tool, and data were analyzed using Stata 15.0. Elagolix proved remarkably more efficient than placebo in easing endometriosis-related pain [Weighted Mean Difference = -0.77, 95% Confidence Interval (-1.00, -0.53), P<0.001], including non-menstrual pelvic pain, dysmenorrhea, and dyspareunia.
Although there was no vital difference in serious adverse effects between the two groups, those receiving the Elagolix reported a higher incidence of general adverse responses (Risk Ratio = 1.34). Thus, Elagolix can successfully curtail pain in premenopausal women with endometriosis in the short- to mid-term. However, careful supervision for potential adverse effects during treatment is essential.
Journal of Gynecology Obstetrics and Human Reproduction
The short- and mid-term efficacy and safety of elagolix in the management of pain associated with endometriosis: A systematic review and meta-analysis
Yue Zhang et al.
Comments (0)